Neuland Laboratories Ltd.

7323.05 +219.80 ▲3.1%

16 April 2024, 12:37:59 PM
Volume: 49,824

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.neulandlabs.com
Market Cap 9,113.39 Cr.
Enterprise Value(EV) 9,074.52 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 247.13 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 28.74 Trailing Twelve Months Ending 2023-12
Industry PE 40.96 Trailing Twelve Months Ending 2023-12
Book Value / Share 945.65 Trailing Twelve Months Ending 2023-12
Price to Book Value 7.51 Calculated using Price: 7,103.25
Dividend Yield 0.14 Period Ending 2023-03
No. of Shares Subscribed 1.28 Cr. 12,829,889 Shares
FaceValue 10
About Neuland Laboratories Ltd.
Neuland is a quality conscious, research driven, reliable source of active pharmaceutical ingredients. Neuland has two world-class API manufacturing facilities close to the city of Hyderabad, capable in handling complex and hazardous reactions. Safety aspects have been given utmost significance may it be plant installation, equipment, systems and personnel to ensure smooth productivity. Dedicated team of manufacturing with incorporation of latest production techniques guarantees delivery of latest intermediate and product to our customers across the globe.

Neuland Laboratories Ltd. Delivery

Delivered Qty
Traded Qty

Neuland Laboratories Ltd. Performance

1 Day
+3.09%
1 Week
+21.19%
1 Month
+23.87%
3 Month
+29.76%
6 Month
+89.78%
1 Year
+252.93%
2 Year
+414.53%
5 Year
+977.39%
10 Year
+2849.51%

Neuland Laboratories Ltd. Fundamental Ratios

9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 11.24 15.64 22.34 5.02 3.48 2.3 10.79 7.85 17.84
Return on Capital Employed (%) 15.75 18.57 15.98 4.07 3.99 7.85 12.81 9.44 20.94
Return on Assets (%) 3.2 5.23 6.65 1.23 1.49 1.37 6.31 4.71 11.04

Neuland Laboratories Ltd. Balance Sheet

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 161 187 546 558 699 710 786 841 994 1,133
Non Curr. Liab. 55 69 54 146 104 163 170 180 147 129
Curr. Liab. 295 268 286 367 327 358 369 363 439 403
Minority Int. 0
Equity & Liab. 512 524 886 1,071 1,130 1,231 1,325 1,383 1,580 1,665
Non Curr. Assets 196 210 511 624 677 716 775 803 819 831
Curr. Assets 316 314 375 447 453 515 550 581 761 834
Misc. Exp. not W/O
Total Assets 512 524 886 1,071 1,130 1,231 1,325 1,383 1,580 1,665

Neuland Laboratories Ltd. Profit and Loss

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 469 510 579 527 667 763 937 951 1,191 1,581
Other Income 1 2 1 5 3 4 16 2 10 15
Total Income 470 512 580 532 670 767 953 953 1,201 1,596
Total Expenditure -403 -430 -473 -477 -608 -661 -790 -808 -919 -1,105
PBIDT 67 82 108 55 62 106 163 145 282 491
Interest -27 -24 -21 -19 -16 -22 -18 -14 -13 -15
Depreciation -15 -16 -19 -22 -26 -31 -40 -49 -53 -57
Taxation -9 -15 -20 -2 -4 -37 -25 -18 -52 -102
Exceptional Items
PAT 16 27 47 12 16 16 81 64 164 317
Minority Interest 0 0
Share Associate
Other Related Items
Consolidated Net Profit 16 27 47 12 16 16 81 64 164 317
Adjusted EPS 18 31 53 14 13 13 63 50 127 246

Neuland Laboratories Ltd. Cash Flow

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 49 13 45 39 11 70 57 189 60 237
Cash Fr. Inv. -10 -14 -20 -42 -116 -77 -49 -84 -96 -62
Cash Fr. Finan. -39 1 -24 0 105 12 -5 -114 38 -136
Net Change 0 0 1 -4 0 5 3 -9 3 40
Cash & Cash Eqvt 1 1 2 3 3 8 11 2 5 45

Neuland Laboratories Ltd. Shareholding Pattern

9 Qtrs 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%) 2024-03 (%)
Promoter 36.22 36.22 36.22 36.14 36.14 36.03 35.97 32.80 32.74
Public 63.78 63.78 63.78 63.86 63.86 63.97 64.03 67.20 67.26
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
No. of Shareholders (in Lacs)

Neuland Laboratories Ltd. Announcements

Mon, 08 Apr 2024
Disclosure under SEBI Takeover Regulations
Neuland Laboratories Limitedᅡᅠhas Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of Indiaᅡᅠ(Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Wed, 03 Apr 2024
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Neuland Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Sun, 31 Mar 2024
Change in Director(s)
Neuland Laboratories Limited has informed the Exchange regarding Change in Director(s) of the company.

Neuland Laboratories Ltd. Technical Scans

Mon, 15 Apr 2024
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Closing Above Previous High Closing Above Previous High
Close Within 52 Week High Zone Close Within 52 Week High Zone

Neuland Laboratories Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 369,773.51 1,530.00 -0.6%
Cipla Ltd. 111,517.58 1,385.80 +0.3%
Dr. Reddy's Laboratories Ltd. 100,257.78 6,033.00 +0.4%
Divi's Laboratories Ltd. 98,636.18 3,758.70 +1.1%
Zydus Lifesciences Ltd. 94,082.88 948.80 +1.5%
Mankind Pharma Ltd. 90,721.26 2,282.70 +0.7%
Apollo Hospitals Enterprise Ltd. 90,631.78 6,285.00 -0.3%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 41.52 1,530.00 -0.6%
Cipla Ltd. Consolidated 2023-12 30.07 1,385.80 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 19.18 6,033.00 +0.4%
Divi's Laboratories Ltd. Consolidated 2023-12 71.32 3,758.70 +1.1%
Zydus Lifesciences Ltd. Consolidated 2023-12 31.64 948.80 +1.5%
Mankind Pharma Ltd. Consolidated 2023-12 52.53 2,282.70 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 114.82 6,285.00 -0.3%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.93 1,530.00 -0.6%
Cipla Ltd. Consolidated 2023-12 4.31 1,385.80 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.73 6,033.00 +0.4%
Divi's Laboratories Ltd. Consolidated 2023-12 7.57 3,758.70 +1.1%
Zydus Lifesciences Ltd. Consolidated 2023-12 4.99 948.80 +1.5%
Mankind Pharma Ltd. Consolidated 2023-12 10.21 2,282.70 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 13.42 6,285.00 -0.3%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,530.00 -0.6%
Cipla Ltd. Consolidated 2023-03 0.02 1,385.80 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,033.00 +0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,758.70 +1.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 948.80 +1.5%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,282.70 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,285.00 -0.3%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,530.00 -0.6%
Cipla Ltd. Consolidated 2023-03 12.85 1,385.80 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,033.00 +0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,758.70 +1.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 948.80 +1.5%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,282.70 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,285.00 -0.3%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,530.00 -0.6%
Cipla Ltd. Consolidated 2023-03 12.85 1,385.80 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,033.00 +0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,758.70 +1.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 948.80 +1.5%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,282.70 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,285.00 -0.3%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,530.00 -0.6%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,385.80 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,033.00 +0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,758.70 +1.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 948.80 +1.5%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,282.70 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,285.00 -0.3%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,530.00 -0.6%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,385.80 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,033.00 +0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,758.70 +1.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 948.80 +1.5%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,282.70 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,285.00 -0.3%

Neuland Laboratories Ltd. FAQ's

What is Neuland Laboratories share price?

Can I buy Neuland Laboratories shares now?

What is the Dividend Yield of Neuland Laboratories?

What is the Market Cap of Neuland Laboratories?

What are the key metrics to analyse Neuland Laboratories?

What is the 52 Week High and Low of Neuland Laboratories?

What is the trend of Neuland Laboratories share price?